Videos

An experienced clinician expands on effective strategies for monitoring patients with mCSPC during and after treatment and reviews patient expectations following disease progression.

Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.

Christopher J. Melani, MD, discusses the results of a trial investigating a combination regimen in a cohort of patients with mantle cell lymphoma.

Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.

A prostate cancer expert shares a brief overview of available first-line therapy options for patients with mCSPC.

Marc Matrana, MD shares his perspective on an mCSPC patient case, focusing on the typical trajectory for patients with biochemical recurrence.

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.

William J. Gradishar, MD, discusses the most recent evolutions in the management of patients with advanced breast cancer.

Dr Nizar Tannir compares data among the 4 approved first-line I/O combination therapy regimens in advanced clear cell RCC.

Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.

Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.

Ian W. Flinn, MD, PhD, discusses his experience using the combination of polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

Kashyap Patel, MD, discusses the current disparities in the myeloma space and the ways in which oncologists are handling them.

Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.

Cary Gross, MD, discusses the key takeaways from his retrospective research examining patients with advanced non–small cell lung cancer and its association with Medicaid insurance, rates of biomarker testing, and patient outcomes.

Peter A. McSweeney, MD, discusses challenges with implementing chimeric antigen receptorT-cell therapy in some community oncology practices.

Charles J. Schneider, MD, FACP, discusses the ways in which the management and care of patients with anal carcinoma has changed over the past decade.

Wesley Burkett, MD, discusses treatment options for endometrial cancer.

Brandon Sheffield, MD, explains the biomarkers that are important to identify before treating a patient who has been diagnosed with non–small cell lung cancer.

Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.

Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.

An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.

Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.

An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.

Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.

Naveen Pemmaraju, MD, shares the critical unmet needs in the myeloproliferative neoplasm treatment landscape.

A key opinion leader details the single-agent therapies currently being investigated for the treatment of myeloproliferative neoplasms.

Dr Pemmaraju explains the rationale for ruxolitinib combination therapies in myeloproliferative neoplasm treatment.

Naveen Pemmaraju, MD, reviews the currently approved systemic treatment options for myelofibrosis and explains how he decides between treatment regimens.

An expert gives an overview of myelofibrosis and its different types and describes the common challenges of diagnosing patients.